Biomedical subjects

Oriol Angerri

Publications and source records attributed to Oriol Angerri.

3 recordsLinked to original sources

PubMed2007

Kidney transplants in patients with bladder augmentation: correlation and evolution.

OBJECTIVE: To review the literature, analyse the evolution of kidney transplants (KT) in patients with bladder augmentation (BA) and investigate the relation between BA and KT. MATERIALS AND METHODS: Six patients with a history of severe lower urinary tract dysfunction and BA, received a KT at our Unit between 1993 and 2003. Three had moderate renal failure at the moment of the BA. The remaining three had end stage renal failure. RESULTS: With a follow-up of 7 years (mean) we have a patient survival of 100% and a graft survival of 83%. No complications occurred between the BA and the KT. The few KT complications were not related to BA. CONCLUSION: When a bladder dysfunction is present, it should be treated before KT. In noncompliant bladders, BA is the best treatment. This can be done to try to avoid end stage renal failure or only to prepare the lower urinary tract for reception of the transplant. The presence of a BA did not worsen the evolution of the KT.

Adolescent↗

PubMed2004

Mucosal fold as a mechanical cause of obstruction in orthotopic ileal neobladder.

Studer's ortothopic neobladder after radical cistectomy has become a good alternative and has improved the patients' quality of life. Voiding dysfunction after surgery is one of the possible late complications with incomplete emptying of the neobladder and chronical urinary retention. The mechanical obstruction may be due to recurrence of the tumor, anterior vaginal wall prolapse, urethrointestinal anastomosis stricture, mucose plug, stone and mucosal fold. We present a clinical case of voiding dysfunction after radical cystectomy with Studer's neobladder. One year after surgery the patient developed obstructive symptoms due to a mucosal fold of the neobladder. An endoscopic incision resolved the obstructive symptoms.

Aged↗

PubMed2003

Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients.

BACKGROUND: Intravesical instillations with bacillus Calmette-Guérin (BCG) is considered the treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the treatment of carcinoma in situ (CIS) of the bladder. METHODS: There is no previous experience with BCG treatment in patients with renal transplantation. Theoretically, immunosuppression is a contraindication because of the risk of severe morbidity and sepsis. We present our experience with endovesical BCG in three renal transplant patients, under immunosuppressive treatment, with high-grade superficial bladder cancer and CIS. RESULTS: Two patients are free of disease at 17 and 60 months. One patient developed disease recurrence and underwent a radical cystectomy. There was neither change in renal function nor any clinical evidence of tuberculous infection. CONCLUSIONS: Intravesical BCG in superficial bladder cancer and/or CIS is a valid option, with no added morbidity to renal transplant patients.

Administration, Intravesical↗